Key result
Anticholinergic polypharmacy is associated with cognitive decline and falls in older adults, necessitating burden scales.
Why the study?
Anticholinergic burden scales are needed to evaluate the risk of anticholinergic adverse events arising from polypharmacy in elderly patients.
Anticholinergic burden scales that incorporate both pharmacological properties and clinical findings are expected to be useful tools for predicting and reducing adverse events in elderly patients with polypharmacy.
May support scale use in geriatric polypharmacy; leaves open prospective validation before practice change.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
山田 et al. (2024) conducted a review in Polypharmacy and anticholinergic burden. Anticholinergic burden scales was evaluated. Polypharmacy involving drugs with anticholinergic properties increases the risk of adverse events such as cognitive decline and falls in older adults, necessitating the use of anticholinergic burden scales for risk assessment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: